Skip to main content
Top
Published in: European Journal of Nutrition 4/2019

01-06-2019 | Original Contribution

Dietary polyunsaturated fatty acids mediate the inverse association of stearoyl-CoA desaturase activity with the risk of fatty liver in dyslipidaemic individuals

Authors: Antonio J. Amor, Montserrat Cofán, Rocío Mateo-Gallego, Ana Cenarro, Fernando Civeira, Emilio Ortega, Emilio Ros, Aleix Sala-Vila

Published in: European Journal of Nutrition | Issue 4/2019

Login to get access

Abstract

Purpose

The activity of stearoyl-CoA desaturase-1 (SCD1) is increased in non-alcoholic fatty liver disease (NAFLD). Polyunsaturated fatty acids (PUFA) inhibit SCD1, but clinical studies on whether all dietary PUFA species are equal in SCD1 inhibition are scarce. Serum phospholipids are an objective proxy of dietary intake of plant-derived PUFA (C18:2n-6, C18:3n-3) and marine-derived PUFA (C20:5n-3, C22:6n-3). In 355 participants with primary dyslipidemia, we cross-sectionally investigated whether the presumed association between surrogate markers of NAFLD and SCD1 activity is mediated by intake of PUFA, and, if it is, what PUFA species are relevant in this regard.

Methods

We determined the fatty acid profile of serum phospholipids by gas chromatography, and used the ratio C16:1n-7/C16:0 as a marker of SCD1 activity. NAFLD was diagnosed by values ≥ 60 in the fatty liver index (FLI), a surrogate recently validated against ultrasonography.

Results

FLI ≥ 60 was detected in 37.5% (n = 133) of study participants. In a multivariate model, SCD1 activity showed an expected significant association with the risk of NAFLD, with odds ratio (OR) (95% confidence interval) of 1.44 (1.04–2.01) for each 0.01 increase. In a model further allowing the stepwise inclusion of plant-derived PUFA, marine-derived PUFA, and total PUFA (vegetable + marine), total PUFA replaced SCD1 activity as a significant (inverse) association of NAFLD, with OR 0.89 (0.81–0.99).

Conclusions

Total PUFA, regardless of their origin, mediates the relationship between SCD1 activity and NAFLD. This provides a new insight in the protective effects of PUFA against NAFLD, heretofore mostly focussed on PUFA species from marine origin.
Literature
2.
go back to reference Cohen P, Miyazaki M, Socci ND et al (2002) Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:240–243CrossRefPubMed Cohen P, Miyazaki M, Socci ND et al (2002) Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:240–243CrossRefPubMed
4.
go back to reference Attie AD, Krauss RM, Gray-Keller MP et al (2002) Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 43:1899–1907CrossRefPubMed Attie AD, Krauss RM, Gray-Keller MP et al (2002) Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 43:1899–1907CrossRefPubMed
6.
go back to reference Chong MF-F, Hodson L, Bickerton AS et al (2008) Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 days of high-carbohydrate feeding. Am J Clin Nutr 87:817–823CrossRefPubMed Chong MF-F, Hodson L, Bickerton AS et al (2008) Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 days of high-carbohydrate feeding. Am J Clin Nutr 87:817–823CrossRefPubMed
11.
go back to reference Ntambi JM (1999) Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res 40:1549–1558PubMed Ntambi JM (1999) Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res 40:1549–1558PubMed
23.
go back to reference European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140. https://doi.org/10.1007/s00125-016-3902-y CrossRef European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140. https://​doi.​org/​10.​1007/​s00125-016-3902-y CrossRef
25.
go back to reference Gómez-Gerique JA, Gutiérrez-Fuentes JA, Montoya MT et al (1999) Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group. Med Clin (Barc) 113:730–735 Gómez-Gerique JA, Gutiérrez-Fuentes JA, Montoya MT et al (1999) Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group. Med Clin (Barc) 113:730–735
28.
go back to reference Burdge GC, Wright P, Jones AE, Wootton SA (2000) A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br J Nutr 84:781–787CrossRefPubMed Burdge GC, Wright P, Jones AE, Wootton SA (2000) A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br J Nutr 84:781–787CrossRefPubMed
36.
go back to reference Aranceta J, Pérez Rodrigo C, Naska A et al (2006) Nut consumption in Spain and other countries. Br J Nutr 96(Suppl 2):S3–11CrossRefPubMed Aranceta J, Pérez Rodrigo C, Naska A et al (2006) Nut consumption in Spain and other countries. Br J Nutr 96(Suppl 2):S3–11CrossRefPubMed
Metadata
Title
Dietary polyunsaturated fatty acids mediate the inverse association of stearoyl-CoA desaturase activity with the risk of fatty liver in dyslipidaemic individuals
Authors
Antonio J. Amor
Montserrat Cofán
Rocío Mateo-Gallego
Ana Cenarro
Fernando Civeira
Emilio Ortega
Emilio Ros
Aleix Sala-Vila
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 4/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-018-1691-4

Other articles of this Issue 4/2019

European Journal of Nutrition 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.